Integral Derivatives’s Jazz Pharmaceuticals JAZZ Stock Holding History

Integral Derivatives’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-2,186	Closed	-$322K	–	1022
2016 Q1	$285K	Buy	+2,186	New	+$272K	0.01%	649
2015 Q2	–	Sell	-2,001	Closed	-$346K	–	1180
2015 Q1	$346K	Buy	+2,001	New	+$343K	0.01%	790

Other funds holding JAZZ

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Integral Derivatives's JAZZ Position: Q2 2016 in Review

Integral Derivatives sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2016, closing a stake of 2,186 shares — an estimated $322K sold.

Integral Derivatives first reported a position in JAZZ in Q1 2015 and held it in 2 quarters. The position peaked at $346K in Q1 2015. 366 funds tracked by Wall St. Rank hold JAZZ as of Q2 2016.

Integral Derivatives reported no remaining Jazz Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Integral Derivatives sold 2,186 Jazz Pharmaceuticals shares in Q2 2016, an estimated $322K.
Integral Derivatives first reported a position in Jazz Pharmaceuticals in Q1 2015 and held it in 2 quarters.
Integral Derivatives's Jazz Pharmaceuticals position peaked at $346K in Q1 2015.
366 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2016.

Based on Integral Derivatives's 13F filing for Q2 2016, filed 5 Aug 2016.